In recent years, experimental systems have developed to analyze genetic and epigenetic regulation of the metastatic phenotype. Numerous studies have uncovered a potent role for transforming oncogenes in metastatic conversion. In addition, it has been shown that oncoprotein products operate in a dose-dependent fashion. The continued expression of oncoproteins is required to induce and regulate metastatic dissemination of tumor cells and, consequently, many of the signal transduction pathways that are controlled by the oncogene products can regulate metastasis. Exogenous growth factors that act through these same pathways also alter metastatic potential. Some primary and immortalized cells can be transformed by oncogenes but remain completely benign and nonmetastatic. Malignant transformation can be achieved in these cells through the cooperative interaction of specific oncogenes or loss of active suppression regulated by recessive genetic determinants. Therefore, it is likely that tumor cells acquire the metastatic phenotype through the cooperative interaction of dominant and recessive genetic alterations. This model is consistent with the correlative data accumulating in studies of human tumor specimens where more malignant carcinomas often contain both activating mutations in oncogenes and either inactivating mutations or loss of tumor-suppressor genes.
Introduction
The dissemination of cancer is a complex process requiring many specialized characteristics. In order for a tumor cell to metastasize, it must have the ability to degrade extracellular matrix structures including basement membranes, which line blood vessels and lymphatics. In addition, the metastatic cell must survive hydrostatic pressure drops in the microvasculature, immune surveillance and, finally, possess the ability to bind to endothelium at the secondary site, extravasate out of the vessel, and form an autonomous lesion (1) (2) (3) .
In the past, the metastatic cell has been viewed as one whose phenotype is extremely unstable. It was thought that through this instability, the large number of phenotypic characteristics could be acquired by a single cell. Thus, the metastatic cascade was viewed as a stochastic process involving a large number of gene products. Highly malignant cells are often aneuploid and possess an unstable karyotype; however, it is difficult to imagine that the large number of properties required for metastasis could be achieved by a single cell if they were truly independent events. The effects of this ge-nomic instability may be limited to relatively few genes that can regulate the metastatic phenotype. In this alternative model, instability facilitates tumor progression or evolution, but the genes are regulatory and not a part of the ultimate metastatic phenotype.
There are numerous experiments that demonstrate that many of these "metastatic properties" can be controlled through the same signal transduction pathways as growth and differentiation signals. For example, platelet-derived growth factor (PDGF) can stimulate protease secretion and motility as well as growth or transformation (4) . Work over the last 5 years on the potential role of oncogenes in metastatic dissemination has provided evidence for this hypothesis (5-7).
In 1985, three groups demonstrated that transformation of NIH 3T3 cells by ras oncogenes resulted in cell lines that expressed the full metastatic phenotype in nude mice (8) (9) (10) . This question was being independently examined by several laboratories including our own (7) and was confirmed and then extended by demonstrating that introduction of ras into many types including primary rat fibroblasts also induced the metastatic phenotype (11, 12) . These experiments raised the question of whether ras was directly regulating metastatic behavior or was inducing a change in phenotypic stability that would cause metastatic dissemination in a ras-independent manner. In addition, it was not clear if ras was inducing the metastatic phenotype through the same mechanism that it could transform these cells. (14) . Our laboratory has shown a correlation between ras gene expression and metastatic potential using ras-transformed 1OT1/2 fibroblasts. In addition, we found that induction of an MMTV-LTR regulated v-H-ras gene in NIH 3T3 cells resulted in increased metastatic potential of these cells (15) . Thus, the dose-dependent regulation of the transformed phenotype by oncogene products was also observed for the metastatic phenotype.
Are the ras-Transformed and Metastatic Phenotypes Genetically Separable? Muschel et al. transformed NIH 3T3 cells with either normal cellular or viral H-ras (16) . Cells transformed by the viral gene were extremely metastatic, whereas the proto-oncogene transformants did not metastasize (16) . In contrast, Bradley et al. reported that NIH 3T3 cells transformed by ras with one of several different mutations including codons 12, 59, and 61, as well as the overexpressed proto-oncogene, were all able to induce the metastatic phenotype (17) . These data can be reconciled if the proto-oncogene is less potent at inducing the metastatic phenotype than the oncogene. This difference can be noted in transformation assays and has now been documented in two systems involving metastatic conversion (18, 19) .
Our laboratory has extended the range of transforming ras alleles that can induce the metastatic phenotype in NIH 3T3 cells to include guanine nucleotide binding mutants in addition to those genes Bradley et al. studied (17) . In no case has a ras gene been found that can transform NIH 3T3 cells without being able to induce the metastatic phenotype in these cells. Thus far, differences in the ability to induce metastasis has been reflected at least partially in differences in transforming potential. This suggests that the mechanism through which ras induces the metastatic phenotype in NIH 3T3 cells is likely the same mechanism by which it transforms these cells. In addition, it has been found that ras oncogenes can convert many different cells into metastatic tumors (7, 12 (23) . In addition, a mutant p53 gene converted mouse bladder carcinoma cells to a highly metastatic tumor (24) . Transformation of many cells by a number of structurally different types of signal transducing gene products results in metastatic conversion. Not all oncogenes, however, can or will induce the metastatic phenotype in a particular tumor system. As mentioned previously, myc-and p53-transformed NIH 3T3 cells are not metastatic (20) . In addition, primary rat embryo fibroblasts transformed by the combination of ElA type 2 and ras were not metastatic, in contrast to these cells transforned by ras alone, which are highly malignant (11) .
Growth Factor Regulation of the Metastatic Phenotype
Many of the oncogenes encode proteins that are directly involved in growth factor signaling. These include sis, which is the B-chain of PDGF, erb-B, which is the receptor for EGF, and fms, which is the receptor for CSF-1 (25) . Since several oncogenes including the tyrosine kinase receptor fms were found to induce the metastatic conversion of NIH 3T3 cells, it would seem likely that signaling through these growth control pathways could normally regulate metastatic potential. We have found that NIH 3T3 cells transformed through the expression of a secreted form of bFGF are highly metastatic. In contrast, transient treatment of ras-or srctransformed NIH 3T3 cells prior to intravenous injection resulted in a profound inhibition of lung colony or experimental metastasis formation (unpublished data). Therefore, growth factor regulation of metastatic properties can be either stimulatory or inhibitory depending on the context of the signal. It has been previously reported that stimulation of B16 murine melanoma cells by the tumor promoting phorbol ester 12-0-tetradecanoylphorbol acetate, which activates protein kinase C, results in a stimulation of experimental metastasis formation after IV injection (26) . This phenomena also occurs in ras-transformed 1OT1/2 cells (unpublished data). Consequently, several signal transducing pathways within cells can regulate metastatic potential.
Another class of soluble regulators of metastatic dissemination exists, which, in many cases, may have profound influence on the course of a tumor. Steroid hormones such as estradiol are important mitogens for many tumors. In the case of breast cancer, a major form of therapy involves blocking the estrogen signals that reach tumor tissue. This can be achieved through ovariectomy or through the administration of anti-estrogens. Estrogens have been found to not only influence the mitotic status of the tumor, but work in experimental systems suggests that estrogen actually stimulates dissemination of the tumor (27) . Clinically important regulators of a tumor can operate through many growth regulating pathways. In some cases, signal transduction may be altered within the tumor cell itself as a result of mutation of a gene product that operates on the pathway, such as a growth factor or steroid receptor. In other cases, a tumor may be receiving signals through the same pathway from a nontumor source such as the stroma with which the tumor is in contact, or from a paracrine or endocrine source elsewhere in the body. We have previously reported that ras transformation of 1OT1/2 fibroblasts induces the metastatic phenotype (15) . In order to learn about the events that facilitate susceptibility to metastatic conversion, these cells were transfected with myc or ras or the sequential combination of both genes in dialyzed calf serum. Under these conditions neither gene alone is transforming (30) . The combination of both genes resulted in potent transformation. Cell lines derived in this way were both anchorage independent and tumorigenic. In contrast to 1OT1/2 cells transformed by ras alone, most myc/ras transformants were nonmetastatic. The myc gene had made 1OT1/2 cells highly susceptible to ras-mediated transformation but had not fully complemented ras in allowing for metastatic conversion.
The ras gene alone can induce the full metastatic phenotype when introduced in the presence of a factor present in fetal calf serum (15, 30) . Consequently, an additional event in cooperation with ras is necessary for metastatic conversion. Introduction of myc into the ras metastatic transformants does not suppress the metastatic phenotype, therefore, metastasis is not inhibited by myc. Finally, it was found that fusion of the nonmetastatic myc/ras transformants to the metastatic ras transformants resulted in mostly nonmetastatic hybrids, indicating that the metastatic phenotype was recessive. The cooperating event in this system was likely to involve the loss of or inactivation of a recessive determinant. It has also been shown in naturally derived tumor cells that fusion of metastatic and nonmetastatic cells resulted in the nonmetastatic hybrids (31) . It is likely, therefore, that the metastatic phenotype is achieved through the cooperative interaction of both dominant and recessive determinants.
Summary and Studies on Human Tumors
An independent line of study has helped elucidate events that are likely important in human tumor progression. In the last 3 years, several teams of researchers have uncovered provocative correlations between specific genetic alterations and malignancy in neoplasia of the breast, lung, and colon. Specific alterations have been detected at several loci in human breast cancer. The most striking finding, however, has been a correlation between malignant behavior and amplification/ overexpression of the HER2/neu (c-erb-B2) growth factor receptor (32) (33) (34) . This gene product is apparently wild-type but through overexpression renders tumor tissue highly sensitive to the neu ligand (35) . The studies described above may provide a mechanistic framework for the interpretation of this clinical data. The neu ligand, whether produced by tumor or by nontumor tissue, may be promoting not only growth but dissemination. The picture is likely not universal for all breast cancer.
Many patients with metastatic breast cancer have tumor cells that express low levels of HER2. In these cases, other lesions such as amplifications of the growth factor int-2 gene, c-myc, and/or alterations ofthe tumorsuppressor genes p53 and Rb, which are often found (36) , may be important determinants of metastatic potential. In human lung cancer, numerous different genetic alterations have been found within single tumors (37) . In small cell as well as nonsmall cell carcinomas, mutations have been found frequently in K-ras, Rb, and p53. In addition, Rb and p53 and other loci on chromosomes 3 and 11 are reduced to homozygosity, suggesting that these loci are functioning as recessive determinants of malignancy and that alterations at each of the two alleles separately contribute to the malignant phenotype. In highly metastatic small cell lung cancer, one of the c-, N-, or L-myc genes are often amplified. These tumors are usually highly disseminated, resistant to therapy, and ultimately lethal.
Vogelstein and co-workers have recently presented a model for tumor progression of colon carcinoma (38) (39) (40) (41) (42) . In this model, loss of tumor-suppressor genes on chromosomes 5, 17 (p53), and 18 (DCC) cooperate with mutational activation of K-ras and p53. The order in which these events occur is variable, but the chromosome 5 and K-ras alterations often occur early and prior to frank carcinoma. In contrast, mutations at the p53 and DCC genes often occur at the transition to carcinoma in situ or later. Since the ras gene activation is often present in benign adenomas, it cannot be responsible for induction of metastasis formation. On the other hand, these mutations have been observed to occur in a different order, suggesting that each alteration may be capable of contributing a progressive effect to tumors at many different stages in the course of tumor evolution. If this is the case, then dissemination of the resulting malignant tumor may be controlled through the cooperative interaction of these and possibly as yet unidentified genetic events. In other words, although one specific genetic lesion may be able to promote transition of a tumor from nonmetastatic to metastatic, the events that preceded this ultimate change are all likely important in the maintenance and regulation of the metastatic phenotype. Thus, the regulation of metastatic dissemination may be dependent on the cooperative interaction of many specific genetic alterations that are present in some malignant tumors. If all or most of the molecular lesions are necessary for its dissemination, this would predict that therapeutic approaches may need to only reverse a single important genetic event. 
